Glucotrack, Inc.

Glucotrack, Inc. will hold a Special Meeting of Stockholders on September 11, 2026, to seek approval for two significant stock issuance proposals. The first proposal involves the issuance of shares to White Lion Capital, LLC, under an ELOC Purchase Agreement for up to $50 million, including commitment shares and warrants. The second proposal concerns the issuance of shares related to Bridge Financing, which raised approximately $7.95 million. Both issuances require stockholder approval under Nasdaq Listing Rule 5635(d) as they may represent more than 20% of the company's outstanding common stock.

Glucotrack, Inc. announced definitive agreements for approximately $5.5 million in financing from institutional investors. This financing package includes a $2.0 million equity financing priced at $0.75 per unit, with each unit comprising one common share and one five-year warrant. Additionally, it includes a $3.5 million follow-on investment in the form of senior secured convertible promissory notes. The company stated that this financing strengthens its balance sheet, provides additional growth capital, and reflects confidence in its long-term strategy.

Glucotrack's wholly-owned subsidiary, Lōkahi Therapeutics Inc., announced significant progress in its LT-100 development strategy. The company aims to simplify the drug's administration from up to 15 intradermal injections to a single subcutaneous injection per visit. Following a Type C meeting with the FDA in May 2026 and a successful nonclinical minipig study, Lōkahi plans to initiate clinical evaluation of this simplified approach as early as the fourth quarter of 2026, with initial results expected in the first half of 2027.

Glucotrack, Inc. entered into an Exchange Agreement on July 22, 2026, with an investor. This agreement partitions a new $900,000 promissory note from an existing $3,600,000 note, which had been previously reduced by $1,588,000 through prior exchanges. The investor may exchange the $900,000 Partitioned Note for shares of the company's common stock, with the number of shares determined by a 'Minimum Price' formula. The exchange is subject to a 9.99% beneficial ownership limitation and involves no additional consideration from the investor.

Glucotrack, Inc. announced its Annual Meeting of Stockholders to be held on August 18, 2026, where shareholders will vote on several key proposals. These include the election of six directors, an advisory vote on executive compensation, and the ratification of the independent auditor. Significantly, the company recently completed a merger with Lokahi Therapeutics, Inc., resulting in Erik Emerson's appointment as CEO and Paul V. Goode's transition to Chief Technology Officer. Shareholders will also vote on approving a reverse stock split at a ratio not exceeding one-for-thirty and a warrant inducement plan for Nasdaq compliance.

Glucotrack, Inc., along with its operating business Lōkahi Therapeutics, announced the successful completion of a bridge financing. This funding is intended to support the company's strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and anticipated capital markets activities. The financing follows the recent business combination between Glucotrack and Lōkahi, with E.F. Hutton & Co. advising on the deal and continuing to support future capital formation opportunities.

Glucotrack, Inc. and Lokahi Therapeutics, Inc. have completed their strategic business combination, with Lokahi Therapeutics becoming the operating and controlling business of the combined public company. Lokahi securityholders will hold approximately 90% of the combined entity on a fully diluted basis, leveraging Glucotrack's public market platform for growth and capital access. The transaction includes a planned private placement financing and establishes Glucotrack's continuous blood glucose monitoring business as a dedicated, wholly owned subsidiary. Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as CTO and CEO of the CBGM subsidiary.

Glucotrack, Inc. announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform for healthcare asset identification and advancement. Lōkahi Therapeutics will become the operating and controlling business, with its securityholders expected to hold approximately 90% of the combined company on a fully diluted basis. A planned private placement financing will support the combined entity, while Glucotrack's legacy continuous blood glucose monitoring (CBGM) business will operate as a wholly owned, separate subsidiary. Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as CTO and CEO of the CBGM subsidiary.

Glucotrack, Inc. received two separate notices from Nasdaq regarding non-compliance with listing rules. The first, on May 11, 2026, cited failure to maintain a minimum bid price of $1.00 per share. The second, on May 15, 2026, indicated the company no longer meets the $2,500,000 minimum stockholders' equity requirement, nor its alternatives. Glucotrack intends to request a hearing by May 18, 2026, to appeal these delisting determinations, which will stay further delisting actions.

Glucotrack, Inc. submitted an Investigational Device Exemption (IDE) application to the U.S. FDA for a U.S. clinical study of its implantable continuous blood glucose monitor (CBGM) technology, marking a significant regulatory milestone. For the first quarter of 2026, the company reported a net loss of $4.33 million, an improvement from $6.83 million in Q1 2025. However, cash and cash equivalents decreased to $3.93 million from $7.38 million at year-end 2025, and management raised substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and negative cash flow.